PDF-CKD and Drug Dosing: Information for Providers

Revised April 2015 Estimation of Kidney Function for Prescription Medication Dosage in Adults Knowledge of kidney function is important for dosage of medications that are excreted by the kidneys Foo. Josh Exley. Learning Objectives. Acute Kidney Injury. Drugs and the Kidney. Chronic Kidney Disease. Normal Kidney function. Kidney Functions. Excretory function. Filter metabolites, toxins, drugs. Homeostatic function. Program Goals. Hepcidin in Chronic Kidney Disease. Treatment of Iron Deficiency Anemia. Assessment of IV Iron in Patients With Non-Dialysis-Dependent CKD. DOPPS Study. Ferric Pyrophosphate. Phosphate Binders. 1 Table 1.1 Distribution of NHANES participants with diabetes, self-reported cardiovascular disease, & single sample markers of CKD, 2007-2012. Data Source: National Health and Nutrition Examination Survey (NHANES), 1988–1994, 1999-2004 & 2005–2012 participants age 20 & older. Note: Cardiovascular disease designation is based on self-report of any CVD condition (see CKD Analytical Methods chapter for detail); CKD is defined as eGFR <60 or ACR ≥30. Abbreviations: ACR, urine albumin/creatinine ratio; CKD, chronic kidney disease; SR CVD, self-reported cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; . not applicable.. based on 3-month 13-week dosing intervals with the flexibility of dosing between weeks 11 and 13GIVENDUEJan1Mar19-Apr2Jan2Mar20-Apr3Jan3Mar21-Apr4Jan4Mar22-Apr5Jan5Mar23-Apr6Jan6Mar24-Apr7Jan7Mar25-Ap Case 201-cv-00779-WBS -CKD Document 142 Filed 04/29/05 Page 2 of 2123456789-1- RD 1234567892 R Lowell Dilworth-Chemical Pathologist. CKD. CKD and Bone disease. Mineral . metabolism controlled by kidneys. , intestine, parathyroid glands and . bone. The . kidney plays a critical role in mineral homeostasis regulation and, therefore, renal disease exerts widespread effects on the skeleton and soft . Definition of CKD. Staging of CKD. Etiology of CKD. How to measure Kidney function . Incidence of ESRD. (per million population, 1990, by HSA, unadjusted). USRDS, 2000. Incidence of ESRD. (per million population, 2000, by HSA, unadjusted) . KDIGO 2017 Clinical Practice Guideline Update. Speaker’s Guide. Summary of KDIGO CKD-MBD Guideline Recommendations. This Speaker’s Guide combines the new recommendation statements . (noted in green) . Namita Singh, MD, FASN. Year 2021. DISCLOSURES. I have no financial relationships with commercial interests to disclose.. This presentation does not include discussion of off-label or investigational use. . Hyperkalemia, Metabolic Acidosis, Malnutrition, Depression & Acute Kidney Injury. Andrew . Narva. , MD, FASN & . Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Andrew . Narva. , MD, FASN. Pharmacokinetics. Dosage adjustment in renal impairment. Dialysis removal of drugs. Ideal drug for a renal patient. Non-renal excretion. No side effects. Active drug. No renally excreted metabolites. Kidney Specialists, Inc.. National Kidney Foundation of Central Ohio. Board of Advisors. Medical Advisory Board. Goals of this talk:. Teach providers how to evaluate CKD patients in their office, to start the diagnostic and treatment plan. Crude prevalence of chronic kidney disease (CKD) among adults with hypertension was over three times as high as that among adults without hypertension (24.6% vs 7.3%, 2017–March 2020). The prevalence of CKD among those with hypertension has remained constant from 2001 through March 2020. Age-standardized trends were consistent with the crude trends.. Approximately 1 in 7 adults in the United States has chronic kidney disease (CKD) stages 1–5. The overall crude prevalence of CKD was 13.9% during 2017–March 2020 and 12.9% during 2001–2004. CKD stages showed little change over time....